Discomfort from an alkaline formulation delivered subcutaneously in humans: Albumin at pH 7 versus pH 10

W. Kenneth Ward, Jessica Castle, Deborah L. Branigan, Ryan G. Massoud, Joseph El Youssef

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background and Objective: There is a paucity of data regarding tolerability of alkaline drugs administered subcutaneously. The aim of this study was to assess the tolerability of alkaline preparations of human albumin delivered subcutaneously to healthy humans. Methods: We compared the tolerability of neutral versus alkaline (pH 10) formulations of human albumin in ten volunteers. With an intent to minimize the time required to reach physiological pH after injection, the alkaline formulation was buffered with a low concentration of glycine (20 mmol/L). Each formulation was given at two rates: over 5 seconds and over 60 seconds.A sixpoint scale was used to assess discomfort. Results: For slow injections, there was a significant difference between pH 7.4 and pH 10 injections (0.4 ± 0.2 vs 1.1 ± 0.2, mean ± SEM; p = 0.025), though the degree of discomfort at pH 10 injections was only 'mild or slight'. For fast injections, the difference between neutral and alkaline formulations was of borderline significance. Inflammation and oedema, as judged by a physician, were very minimal for all injections, irrespective of pH. Conclusion: For subcutaneous drug administration (especially when delivered slowly), there was more discomfort associated with alkaline versus neutral formulations of albumin, though the discomfort was mild. This study suggests that there is little discomfort and inflammation resulting from subcutaneous administration of protein drugs formulated with weak buffers at alkaline pH.

Original languageEnglish (US)
Pages (from-to)433-438
Number of pages6
JournalClinical Drug Investigation
Volume32
Issue number7
DOIs
StatePublished - 2012

Fingerprint

Albumins
Injections
Pharmaceutical Preparations
Inflammation
Glycine
Volunteers
Edema
Buffers
Physicians
Proteins

Keywords

  • Albumin-human
  • Injection-site-pain
  • Subcutaneous.

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Discomfort from an alkaline formulation delivered subcutaneously in humans : Albumin at pH 7 versus pH 10. / Ward, W. Kenneth; Castle, Jessica; Branigan, Deborah L.; Massoud, Ryan G.; El Youssef, Joseph.

In: Clinical Drug Investigation, Vol. 32, No. 7, 2012, p. 433-438.

Research output: Contribution to journalArticle

@article{8347ff57dcaf4467a42cc09ef9368adc,
title = "Discomfort from an alkaline formulation delivered subcutaneously in humans: Albumin at pH 7 versus pH 10",
abstract = "Background and Objective: There is a paucity of data regarding tolerability of alkaline drugs administered subcutaneously. The aim of this study was to assess the tolerability of alkaline preparations of human albumin delivered subcutaneously to healthy humans. Methods: We compared the tolerability of neutral versus alkaline (pH 10) formulations of human albumin in ten volunteers. With an intent to minimize the time required to reach physiological pH after injection, the alkaline formulation was buffered with a low concentration of glycine (20 mmol/L). Each formulation was given at two rates: over 5 seconds and over 60 seconds.A sixpoint scale was used to assess discomfort. Results: For slow injections, there was a significant difference between pH 7.4 and pH 10 injections (0.4 ± 0.2 vs 1.1 ± 0.2, mean ± SEM; p = 0.025), though the degree of discomfort at pH 10 injections was only 'mild or slight'. For fast injections, the difference between neutral and alkaline formulations was of borderline significance. Inflammation and oedema, as judged by a physician, were very minimal for all injections, irrespective of pH. Conclusion: For subcutaneous drug administration (especially when delivered slowly), there was more discomfort associated with alkaline versus neutral formulations of albumin, though the discomfort was mild. This study suggests that there is little discomfort and inflammation resulting from subcutaneous administration of protein drugs formulated with weak buffers at alkaline pH.",
keywords = "Albumin-human, Injection-site-pain, Subcutaneous.",
author = "Ward, {W. Kenneth} and Jessica Castle and Branigan, {Deborah L.} and Massoud, {Ryan G.} and {El Youssef}, Joseph",
year = "2012",
doi = "10.2165/11632840-000000000-00000",
language = "English (US)",
volume = "32",
pages = "433--438",
journal = "Clinical Drug Investigation",
issn = "1173-2563",
publisher = "Adis International Ltd",
number = "7",

}

TY - JOUR

T1 - Discomfort from an alkaline formulation delivered subcutaneously in humans

T2 - Albumin at pH 7 versus pH 10

AU - Ward, W. Kenneth

AU - Castle, Jessica

AU - Branigan, Deborah L.

AU - Massoud, Ryan G.

AU - El Youssef, Joseph

PY - 2012

Y1 - 2012

N2 - Background and Objective: There is a paucity of data regarding tolerability of alkaline drugs administered subcutaneously. The aim of this study was to assess the tolerability of alkaline preparations of human albumin delivered subcutaneously to healthy humans. Methods: We compared the tolerability of neutral versus alkaline (pH 10) formulations of human albumin in ten volunteers. With an intent to minimize the time required to reach physiological pH after injection, the alkaline formulation was buffered with a low concentration of glycine (20 mmol/L). Each formulation was given at two rates: over 5 seconds and over 60 seconds.A sixpoint scale was used to assess discomfort. Results: For slow injections, there was a significant difference between pH 7.4 and pH 10 injections (0.4 ± 0.2 vs 1.1 ± 0.2, mean ± SEM; p = 0.025), though the degree of discomfort at pH 10 injections was only 'mild or slight'. For fast injections, the difference between neutral and alkaline formulations was of borderline significance. Inflammation and oedema, as judged by a physician, were very minimal for all injections, irrespective of pH. Conclusion: For subcutaneous drug administration (especially when delivered slowly), there was more discomfort associated with alkaline versus neutral formulations of albumin, though the discomfort was mild. This study suggests that there is little discomfort and inflammation resulting from subcutaneous administration of protein drugs formulated with weak buffers at alkaline pH.

AB - Background and Objective: There is a paucity of data regarding tolerability of alkaline drugs administered subcutaneously. The aim of this study was to assess the tolerability of alkaline preparations of human albumin delivered subcutaneously to healthy humans. Methods: We compared the tolerability of neutral versus alkaline (pH 10) formulations of human albumin in ten volunteers. With an intent to minimize the time required to reach physiological pH after injection, the alkaline formulation was buffered with a low concentration of glycine (20 mmol/L). Each formulation was given at two rates: over 5 seconds and over 60 seconds.A sixpoint scale was used to assess discomfort. Results: For slow injections, there was a significant difference between pH 7.4 and pH 10 injections (0.4 ± 0.2 vs 1.1 ± 0.2, mean ± SEM; p = 0.025), though the degree of discomfort at pH 10 injections was only 'mild or slight'. For fast injections, the difference between neutral and alkaline formulations was of borderline significance. Inflammation and oedema, as judged by a physician, were very minimal for all injections, irrespective of pH. Conclusion: For subcutaneous drug administration (especially when delivered slowly), there was more discomfort associated with alkaline versus neutral formulations of albumin, though the discomfort was mild. This study suggests that there is little discomfort and inflammation resulting from subcutaneous administration of protein drugs formulated with weak buffers at alkaline pH.

KW - Albumin-human

KW - Injection-site-pain

KW - Subcutaneous.

UR - http://www.scopus.com/inward/record.url?scp=84862020539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862020539&partnerID=8YFLogxK

U2 - 10.2165/11632840-000000000-00000

DO - 10.2165/11632840-000000000-00000

M3 - Article

C2 - 22568666

AN - SCOPUS:84862020539

VL - 32

SP - 433

EP - 438

JO - Clinical Drug Investigation

JF - Clinical Drug Investigation

SN - 1173-2563

IS - 7

ER -